In 2021, the world changed for drug research and discovery when researchers published advances that used AI and machine learning to predict the structure of human proteins from their sequences. With discoveries like this, scientists are launching the generative biology revolution where they strive to leave the guesswork behind and instead use computers to quickly tailor biological molecules for therapeutic purposes. In this episode, we speak with Alan Russell, vice president of Biologics at Amgen and review what generative biology is and how it helps scientists understand proteins from their amino acid building blocks to their folded, three-dimensional structures. We also discuss how this new field improves the quality and complexity of biologic drug candidates and the speed with which researchers generate them.

Speaker
Alan Russell, PhD
Vice President
Biologics
Amgen